April 21, 2026 9:45–10:03 AM
Broadway 3
iNOvodel is a medical technology company commercializing a novel system for delivering inhaled nitric oxide (iNO) therapy.
Our proprietary platform generates highly concentrated iNO using safe, low-cost chemicals and rapidly mixes it to minimize harmful NO₂ formation—offering improved safety, portability, ease of use, and lower cost compared to existing hospital-based systems.
iNOvodel aims to expand iNO therapy to broader patient populations and new clinical settings.
